RVMD insider transaction filings
Revolution Medicines, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen RVMD transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 15 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 78 legs across 15 filings by 9 insiders — 383,601 shares, $77,942,264 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 35,938 shares @ $209.26 ($7,520,440) by GOLDSMITH MARK A, filed 2026-08-25.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| GOLDSMITH MARK A — See Remarks, Director | 2 | — | 20 legs · 99,988 sh · $20,778,045 | 2 |
| Kelsey Stephen Michael — See Remarks | 2 | — | 10 legs · 98,100 sh · $19,834,322 | 4 |
| Kim Lorence H. — Director | 2 | — | 14 legs · 73,090 sh · $14,967,125 | — |
| Cislini Jeff — SVP & General Counsel | 2 | — | 8 legs · 60,260 sh · $12,574,878 | 4 |
| Anders Jack — Chief Financial Officer | 2 | — | 6 legs · 24,053 sh · $4,174,118 | 2 |
| Mancini Anthony — See Remarks | 2 | — | 7 legs · 17,222 sh · $3,507,256 | 2 |
| Patel Sushil — Director | 1 | — | 9 legs · 5,580 sh · $1,048,967 | 2 |
| Horn Margaret A — Chief Operating Officer | 1 | — | 2 legs · 4,967 sh · $989,613 | — |
| Sandler Alan B. — Chief Development Officer | 1 | — | 2 legs · 341 sh · $67,941 | — |
Recent Form 4 filings — Revolution Medicines, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Kelsey Stephen Michael — See Remarks | Sale (S): 85 @ $195.01 · Sale (S): 5,484 @ $199.30 | EDGAR |
| 2026-09-18 | 4 | Mancini Anthony — See Remarks | Sale (S): 27 @ $195.05 · Sale (S): 1,747 @ $199.30 | EDGAR |
| 2026-09-18 | 4 | Sandler Alan B. — Chief Development Officer | Sale (S): 5 @ $194.96 · Sale (S): 336 @ $199.30 | EDGAR |
| 2026-09-18 | 4 | Cislini Jeff — SVP & General Counsel | Sale (S): 52 @ $195.01 · Sale (S): 3,314 @ $199.30 | EDGAR |
| 2026-09-18 | 4 | GOLDSMITH MARK A — See Remarks, Director | Sale (S): 213 @ $195.01 · Sale (S): 13,775 @ $199.30 | EDGAR |
| 2026-09-18 | 4 | Horn Margaret A — Chief Operating Officer | Sale (S): 76 @ $195.01 · Sale (S): 4,891 @ $199.30 | EDGAR |
| 2026-09-18 | 4 | Anders Jack — Chief Financial Officer | Sale (S): 61 @ $195 · Sale (S): 3,992 @ $199.30 | EDGAR |
| 2026-09-15 | 4 | Kelsey Stephen Michael — See Remarks | Option exercise (M): 52,500 @ $42.45 · Option exercise (M): 40,031 @ $40.74 · Sale (S): 800 @ $198.55 · Sale (S): 11,833 @ $200.11 · Sale (S): 13,368 @ $200.78 · Sale (S): 21,447 @ $201.75 · +6 more | EDGAR |
| 2026-09-14 | 4 | Mancini Anthony — See Remarks | Option exercise (M): 9,363 @ $33.62 · Sale (S): 6,019 @ $203.28 · Sale (S): 5,530 @ $204.14 · Sale (S): 2,420 @ $205.05 · Sale (S): 1,179 @ $206.10 · Sale (S): 300 @ $207.17 · +1 more | EDGAR |
| 2026-09-10 | 4 | Kim Lorence H. — Director | Sale (S): 706 @ $206.60 · Sale (S): 999 @ $207.33 · Sale (S): 3,587 @ $208.55 · Sale (S): 2,853 @ $209.56 · Sale (S): 4,730 @ $210.50 · Sale (S): 3,844 @ $211.36 · +1 more | EDGAR |
| 2026-09-02 | 4 | Kim Lorence H. — Director | Sale (S): 300 @ $200.56 · Sale (S): 6,597 @ $201.47 · Sale (S): 12,919 @ $202.48 · Sale (S): 26,160 @ $203.55 · Sale (S): 7,271 @ $204.35 · Sale (S): 2,128 @ $205.19 · +1 more | EDGAR |
| 2026-08-25 | 4 | GOLDSMITH MARK A — See Remarks, Director | Option exercise (M): 80,000 @ $4.73 · Sale (S): 5,128 @ $207.23 · Sale (S): 24,917 @ $208.37 · Sale (S): 35,938 @ $209.26 · Sale (S): 3,813 @ $210.25 · Sale (S): 6,583 @ $211.33 · +14 more | EDGAR |
| 2026-08-25 | 4 | Cislini Jeff — General Counsel | Option exercise (M): 29,680 @ $18.56 · Option exercise (M): 26,600 @ $21.61 · Sale (S): 3,400 @ $207.24 · Sale (S): 17,323 @ $208.37 · Sale (S): 25,817 @ $209.25 · Sale (S): 2,540 @ $210.26 · +4 more | EDGAR |
| 2026-07-01 | 4 | Patel Sushil — Director | Option exercise (M): 2,955 @ $37.54 · Sale (S): 300 @ $183.17 · Sale (S): 900 @ $184.59 · Sale (S): 1,100 @ $185.90 · Sale (S): 858 @ $186.92 · Sale (S): 300 @ $187.83 · +5 more | EDGAR |
| 2026-06-26 | 4 | Anders Jack — Chief Financial Officer | Option exercise (M): 20,000 @ $18.56 · Sale (S): 4,553 @ $167.34 · Sale (S): 9,496 @ $168.20 · Sale (S): 5,651 @ $169.24 · Sale (S): 300 @ $170.32 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Kim Lorence H. — Director | Grant/award (A): 1,191 @ $0 · Grant/award (A): 3,127 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | ANDERSON ELIZABETH M — Director | Grant/award (A): 1,191 @ $0 · Grant/award (A): 3,127 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Horning Sandra — Director | Grant/award (A): 1,191 @ $0 · Grant/award (A): 3,127 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Clyburn Frank — Director | Grant/award (A): 1,191 @ $0 · Grant/award (A): 3,127 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Patel Sushil — Director | Grant/award (A): 1,191 @ $0 · Grant/award (A): 3,127 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Borellini Flavia — Director | Grant/award (A): 1,191 @ $0 · Grant/award (A): 3,127 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Borisy Alexis — Director | Grant/award (A): 1,191 @ $0 · Grant/award (A): 3,127 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Mancini Anthony — See Remarks | Sale (S): 4,615 @ $156.12 | EDGAR |
| 2026-06-18 | 4 | Cislini Jeff — General Counsel | Sale (S): 2,157 @ $156.12 | EDGAR |
| 2026-06-18 | 4 | Anders Jack — Chief Financial Officer | Sale (S): 2,722 @ $156.12 | EDGAR |
| 2026-06-18 | 4 | Kelsey Stephen Michael — See Remarks | Sale (S): 4,175 @ $156.12 | EDGAR |
| 2026-06-18 | 4 | GOLDSMITH MARK A — See Remarks, Director | Sale (S): 10,020 @ $156.12 | EDGAR |
| 2026-06-17 | 4 | Horn Margaret A — Chief Operating Officer | Option exercise (M): 15,546 @ $40.74 · Option exercise (M): 44,854 @ $29.80 · Sale (S): 60,400 @ $160.17 · Sale (S): 3,575 @ $156.12 · Option exercise (M): 573 @ $40.74 · Option exercise (M): 3,302 @ $29.80 · +7 more | EDGAR |
| 2026-06-15 | 4 | Horn Margaret A — Chief Operating Officer | Option exercise (M): 1,094 @ $42.45 · Option exercise (M): 8,906 @ $40.74 · Sale (S): 1,315 @ $144.28 · Sale (S): 885 @ $145.15 · Sale (S): 700 @ $146.04 · Sale (S): 500 @ $147.27 · +5 more | EDGAR |
| 2026-05-28 | 4 | Mancini Anthony — See Remarks | Option exercise (M): 3,121 @ $33.62 · Sale (S): 700 @ $153.30 · Sale (S): 2,000 @ $154.06 · Sale (S): 421 @ $154.82 · Option exercise (M): 3,121 (derivative) @ $0 | EDGAR |
| 2026-04-29 | 4 | Mancini Anthony — See Remarks | Option exercise (M): 3,120 @ $33.62 · Sale (S): 1,671 @ $131.66 · Sale (S): 1,049 @ $132.88 · Sale (S): 400 @ $134.34 · Option exercise (M): 3,120 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | GOLDSMITH MARK A — See Remarks, Director | Option exercise (M): 23,244 @ $4.09 · Option exercise (M): 96,756 @ $4.73 · Sale (S): 120,000 @ $150.09 · Option exercise (M): 23,244 (derivative) @ $0 · Option exercise (M): 96,756 (derivative) @ $0 | EDGAR |
| 2026-03-26 | 4 | Mancini Anthony — See Remarks | Option exercise (M): 37,450 @ $33.62 · Sale (S): 1,800 @ $93.22 · Sale (S): 3,128 @ $94.16 · Sale (S): 21,086 @ $95.49 · Sale (S): 11,036 @ $96.43 · Sale (S): 400 @ $97.21 · +1 more | EDGAR |
| 2026-03-19 | 4 | Wei Lin — Chief Medical Officer | Sale (S): 2,073 @ $99.48 | EDGAR |
| 2026-03-19 | 4 | Anders Jack — Chief Financial Officer | Sale (S): 2,753 @ $99.48 | EDGAR |
| 2026-03-19 | 4 | Cislini Jeff — General Counsel | Sale (S): 1,795 @ $99.48 · Sale (S): 1,163 @ $97.44 | EDGAR |
| 2026-03-19 | 4 | Wang Xiaolin — See Remarks | Sale (S): 2,010 @ $99.48 | EDGAR |
| 2026-03-19 | 4 | Kelsey Stephen Michael — See Remarks | Sale (S): 4,302 @ $99.48 | EDGAR |
| 2026-03-19 | 4 | Horn Margaret A — Chief Operating Officer | Sale (S): 4,583 @ $99.48 | EDGAR |
| 2026-03-19 | 4 | GOLDSMITH MARK A — See Remarks, Director | Sale (S): 12,871 @ $99.48 | EDGAR |
| 2026-03-06 | 4 | ANDERSON ELIZABETH M — Director | Gift (G): 15,000 @ $0 · Gift (G): 15,000 @ $0 | EDGAR |
| 2026-03-03 | 4 | Wang Xiaolin — See Remarks | Grant/award (A): 15,100 @ $0 · Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Wei Lin — Chief Medical Officer | Grant/award (A): 15,100 @ $0 · Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Cislini Jeff — General Counsel | Grant/award (A): 14,500 @ $0 · Grant/award (A): 32,500 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Anders Jack — Chief Financial Officer | Grant/award (A): 20,200 @ $0 · Grant/award (A): 45,400 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Kelsey Stephen Michael — See Remarks | Grant/award (A): 21,100 @ $0 · Grant/award (A): 47,600 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Horn Margaret A — Chief Operating Officer | Grant/award (A): 21,100 @ $0 · Grant/award (A): 47,600 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | GOLDSMITH MARK A — See Remarks, Director | Grant/award (A): 57,100 @ $0 · Option exercise (M): 30,000 @ $4.09 · Sale (S): 700 @ $98.17 · Sale (S): 3,500 @ $99.76 · Sale (S): 3,620 @ $100.73 · Sale (S): 21,329 @ $101.60 · +11 more | EDGAR |
| 2026-02-10 | 4 | GOLDSMITH MARK A — See Remarks, Director | Option exercise (M): 24,010 @ $0.54 · Option exercise (M): 24,010 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Cislini Jeff — General Counsel | Sale (S): 908 @ $115.60 | EDGAR |
Recent 8-K events — Revolution Medicines, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2026-08-26 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-16 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RVMD returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →